The Independent Data Monitoring Committee recommended transitioning patients in the placebo arm to garetosmab as soon as possible. Topline data were announced from a phase 3 trial evaluating ...

Imagine a bruise that never heals — instead, it hardens into bone. A small swelling that doesn’t fade but permanently locks a joint. For people living with Fibrodysplasia Ossificans Progressiva (FOP), ...

BRISBANE, Calif.--(BUSINESS WIRE)--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of severe bone and connective tissue disorders, today ...

Fibrodysplasia ossificans progressiva (FOP) is an extremely rare congenital condition that causes the body to grow a second skeleton, rendering patients immobile. When you purchase through links on ...

FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation Garetosmab is the first and only treatment to demonstrate a dramatic ...

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the Health Canada approval of Sohonos (palovarotene capsules), an oral selective retinoic-acid receptor gamma ...

FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If ...

WHAT TRIGGERS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)? Fibrodysplasia Ossificans Progressiva (FOP)—also known as stone man syndrome—is caused by a mutation in a specific gene responsible for ...

Fibrodysplasia ossificans progressiva (FOP), sometimes referred to as Stone Man Syndrome, is an extremely rare disease of the connective tissue. A mutation of the body's repair mechanism causes ...